This content was released on 28/08/2019 and will expire on 28/08/2020.
These five 3-minute videos summarise the role of primary care services in helping people with diabetes achieve multifactorial health. This includes foot care, kidney health, eye care, mental health and diet
This content was released on 06/01/2021 and will expire on 06/01/2022.
Hypoglycaemia is a risk for anyone taking insulin, and can be difficult to balance against efforts for glycaemic control due to the various overlapping factors that can lead to an episode.
This 5-minute video, steered by Professor Simon Heller of the University of Sheffield, presents the key elements in reducing the risk of hypoglycaemia, including selection of insulin analogue, glucose monitoring, lifestyle behaviours, and education for patients and their families.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This content was released on 18/08/2020 and will expire on 18/08/2021.
With no pharmacotherapies currently approved to treat NASH, management of this condition is a complicated issue. Furthermore, NASH typically presents alongside comorbidities, so how can we best manage it?
This 5-minute video, steered by Dr. Stephen Harrison, discusses guideline recommendations for treating NASH through a multifactorial approach, the evidence for different strategies, and how to integrate this with management of type 2 diabetes and obesity.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This content was released on 26/01/2021 and will expire on 26/01/2022.
CAPTURE was a non-interventional, cross-sectional study that assessed the prevalence of cardiovascular disease in people with type 2 diabetes; a pre-specified secondary analysis evaluated the use of glucose-lowering agents with a proven cardiovascular benefit.
Join principal investigator Dr Sérgio Vencio for a 5-minute summary of this analysis, presented in a poster at the EASD 2020 annual meeting.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This content was released on 18/02/2021 and will expire on 18/02/2022.
The prevalence of metabolic-associated fatty liver disease (MAFLD) is estimated to be 80-90% among people with obesity, diabetes and metabolic syndrome. A notable proportion of these will progress to non-alcoholic steatohepatitis (NASH), which increases the risk of fatal and non-fatal cardiorenal disease, and is a leading indication for liver transplantation. It is therefore essential to consider MAFLD and NASH among people with metabolic diseases, including obesity and diabetes.
This 5-minute video, steered by Professor William Alazawi, summarises the pathophysiology of NASH, its links with metabolic diseases, and how it progresses to poor outcomes.
DUAL V and DUAL VII investigated the safety and efficacy of IDegLira in participants with insufficiently controlled type 2 diabetes. The results showed that IDegLira improved glycaemic control, and compared to insulin therapy alone, reduced the risk of weight gain and hypoglycaemia.
In this 5-minute video, Professor Tina Vilsbøll presents a post-hoc analysis aiming to answer two outstanding questions. Firstly, for those participants taking a higher dose of insulin before switching to IDegLira, did glycaemic control decline before it improved? And secondly, did the pre-trial insulin dose influence the effects of IDegLira?
HbA1c is the traditional primary metric for monitoring glycaemia, but it does not give us a full picture of glycaemic control. Does shorter-term glycaemic variation have an impact on outcomes? Does longer-term fluctuation in HbA1c affect the disease course?
This 5-minute video, steered by Professor Dace Trence, outlines the outcomes associated with both short- and longer-term glycaemic variability in type 2 diabetes.
SGLT2 inhibitors are a class of antihyperglycaemic agents that have been found to also offer cardiovascular and renal benefits. But how do they work and how are they used in clinical practice?
Steered by Professor Hiddo Lambers Heerspink, this video summarises their mode of action, clinical considerations for initiating therapy, and monitoring for adverse events.
It is estimated that up to 90% of people with obesity, diabetes and metabolic syndrome are living with NAFLD, around 1 in 5 of whom will progress to NASH. Currently, the only way to confirm a diagnosis of NASH is through liver biopsy, so how can we best identify patients at high risk?
This 5-minute video is steered by Professor Arun Sanyal, and provides an overview of best-practice screening approaches for identifying patients at higher risk of NASH.
A video covering selected abstracts presented at the 2021 American Diabetes Association’s Scientific Sessions regarding SGLT2 inhibitors. Watch for the key takeaways from:
- Dapagliflozin safety and efficacy by glycaemic status in CKD (analysis of DAPA-CKD)
- Ertugliflozin cardiorenal outcomes by baseline glucose-lowering agent (analysis of VERTIS CV)
- Global use of SGLT2is and GLP-1 RAs in T2D (results from DISCOVER)
An animated summary of the key highlights for GLP-1 receptor agonists from the 2021 American Diabetes Association’s Scientific Sessions. Watch for a quick overview of: